Abstract:An important stage in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) life cycle is the binding of the spike (S) protein to the angiotensin converting enzyme-2 (ACE2) host cell receptor. Therefore, to explore conserved features in spike protein dynamics and to identify potentially novel regions for drugging, we measured spike protein variability derived from 791 viral genomes and studied its properties by molecular dynamics (MD) simulation. The findings indicated that S2 subunit (heptad-repeat 1 (HR1), central helix (CH), and connector domain (CD) domains) showed low variability, low fluctuations in MD, and displayed a trimer cavity. By contrast, the receptor binding domain (RBD) domain, which is typically targeted in drug discovery programs, exhibits more sequence variability and flexibility. Interpretations from MD simulations suggest that the monomer form of spike protein is in constant motion showing transitions between an “up” and “down” state. In addition, the trimer cavity may function as a “bouncing spring” that may facilitate the homotrimer spike protein interactions with the ACE2 receptor. The feasibility of the trimer cavity as a potential drug target was examined by structure based virtual screening. Several hits were identified that have already been validated or suggested to inhibit the SARS-CoV-2 virus in published cell models. In particular, the data suggest an action mechanism for molecules including Chitosan and macrolides such as the mTOR (mammalian target of Rapamycin) pathway inhibitor Rapamycin. These findings identify a novel small molecule binding-site formed by the spike protein oligomer, that might assist in future drug discovery programs aimed at targeting the coronavirus (CoV) family of viruses.

A Topology-Matching Spike Protein-Capping Tetrahedral DNA Nanocrown for SARS-CoV-2 Neutralization

Spatially Patterned Neutralizing Icosahedral DNA Nanocage for Efficient SARS-CoV-2 Blocking

Spike Protein Targeting" Nano-Glue" that Captures and Promotes SARS-CoV-2 Elimination

Targeting Receptor Binding Domain and Cryptic Pocket of Spike glycoprotein from SARS-CoV-2 by biomolecular modeling

Engineered Trimeric ACE2 Binds Viral Spike Protein and Locks It in “Three-Up” Conformation to Potently Inhibit SARS-CoV-2 Infection

A Potent Neutralizing Nanobody Targeting the Spike Receptor-Binding Domain of SARS-CoV-2 and the Structural Basis of Its Intimate Binding

Mapping Cross-Variant Neutralizing Sites on the SARS-CoV-2 Spike Protein.

Structures of the SARS-CoV-2 spike glycoprotein and applications for novel drug development

A nanomaterial targeting the spike protein captures SARS-CoV-2 variants and promotes viral elimination

Highly Conserved Homotrimer Cavity Formed by the SARS-CoV-2 Spike Glycoprotein: A Novel Binding Site

Broadly neutralizing aptamers to SARS-CoV-2: a diverse panel of modified DNA antiviral agents

Engineered Trimeric ACE2 Binds and Locks “Three-Up” Spike Protein to Potently Inhibit SARS-CoVs and Mutants

A Potent Neutralizing Human Antibody Reveals the N-terminal Domain of the Spike Protein of SARS-CoV-2 As a Site of Vulnerability

Rapid design and development of CRISPR-Cas13a targeting SARS-CoV-2 spike protein

Discovery of Novel Spike Inhibitors against SARS-CoV-2 Infection

A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2

The Spike Glycoprotein of Highly Pathogenic Human Coronaviruses: Structural Insights for Understanding Infection, Evolution and Inhibition.

Exploring Distinct Modes of Inter-Spike Cross-Linking for Enhanced Neutralization by SARS-CoV-2 Antibodies

A potent neutralizing nanobody targeting a unique epitope on the receptor-binding domain of SARS-CoV-2 spike protein

Structure and inhibition of SARS-CoV-2 spike refolding in membranes

Covalently Engineered Protein Minibinders with Enhanced Neutralization Efficacy against Escaping SARS-CoV-2 Variants